Anemia, diabetes, and chronic kidney disease

Diabetes Care

Volumn 32, Issue 7, 2009, Pages 1320-1326

  Mehdi, Uzma ^a   Toto, Robert D ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERROUS GLUCONATE; FUMARIC ACID; IRON; IRON DEXTRAN; LOSARTAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SULFATE;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFECT; ERYTHROCYTE APLASIA; GASTROINTESTINAL TOXICITY; HUMAN; IRON DEFICIENCY; IRON THERAPY; MORBIDITY; MORTALITY; NEPHROTIC SYNDROME; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; QUALITY CONTROL; RATING SCALE; RENAL PROTECTION; REVIEW; TREATMENT RESPONSE;

ANEMIA; ANIMALS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NEPHROTIC SYNDROME; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67650082797     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0779     Document Type: Review

References (66)

1. USRDS. United States Renal Data Systems Annual Data Report. Am J Kid Dis 2007;49(Suppl. 1):S10-S294
2. Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008;21:300-307
3. Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, Levey AS, Sarnak MJ. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005;16:3403-3410
4. Toto RD. Heart disease in diabetic patients. Semin Nephrol 2005;25:372-378
5. New JP, Aung T, Baker PG, Yongsheng G, Pylypczuk R, Houghton J, Rudenski A, New RP, Hegarty J, Gibson JM, O'Donoghue DJ, Buchan IE. The high prevalence of unrecognized anaemia in patients with diabetes and chronic kidney disease: a population-based study. Diabet Med 2008;25:564-569
6. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, the CREATE Investigators. Normalization of Hb level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084
7. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004;66:1131-1138
8. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J. Canadian randomized trial of Hb maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005;46:799-811
9. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004;15:148-156
10. Horl WH, Vanrenterghem Y, Canaud B, Mann J, Teatini U, Wanner C, Wikström B. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. Nephrol Dial Transplant 2005;20(Suppl. 3):iii25-iii32
11. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, the CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098
12. Fishbane S, Nissenson AR. The new FDA label for erythropoietin treatment: how does it affect Hb target? Kidney Int 2007;72:806-813
13. Macdougall IC, Eckardt KU, Locatelli F. Latest US KDOQI Anaemia Guidelines update-what are the implications for Europe? Nephrol Dial Transplant 2007;22:2738-2742
14. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-1408
15. Thomas MC. Anemia in diabetes: marker or mediator of microvascular disease? Nat Clin Pract Nephrol 2007;3:20-30
16. Thomas MC, Tsalamandris C, MacIsaac RJ, Jerums G. The epidemiology of Hb levels in patients with type 2 diabetes. Am J Kidney Dis 2006;48:537-545
17. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 2009;4:57-61
18. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, Aros CA, Caorsi I, Vío CP, Ruiz-Ortega M, Egido J. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int 2003;(Suppl):S64-S70
19. Thomas MC, MacIsaac RJ, Tsalamandris C, Jerums G. Elevated iron indices in patients with diabetes. Diabet Med 2004;21:798-802
20. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997;51:622-630
21. Winkler AS, Marsden J, Chaudhuri KR, Hambley H, Watkins PJ. Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med 1999;16:813-819
22. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001;24:495-499
23. Howard RL, Buddington B, Alfrey AC. Urinary albumin, transferrin and iron excretion in diabetic patients. Kidney Int 1991;40:923-926
24. Vaziri ND. Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis 2001;38:1-8
25. Marathias KP, Agroyannis B, Mavromoustakos T, Matsoukas J, Vlahakos DV. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 2004;4:483-486
26. Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD. The effect of losartan on Hb concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 2008;73:630-636
27. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004;24:453-460
28. Rossert J, Froissart M. Role of anemia in progression of chronic kidney disease. Semin Nephrol 2006;26:283-289
29. Mohanram A, Toto RD. Outcome studies in diabetic nephropathy. Semin Nephrol 2003;23:255-271
30. Norman JT, Fine LG. Intrarenal oxygenation in chronic renal failure. Clin Exp Pharmacol Physiol 2006;33:989-996
31. Iwano M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 2004;13:279-284
32. Garcia DL, Anderson S, Rennke HG, Brenner BM. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A 1988;85:6142-6146
33. Lafferty HM, Anderson S, Brenner BM. Anemia: a potent modulator of renal hemodynamics in models of progressive renal disease. Am J Kidney Dis 1991;17(Suppl. 1):2-7
34. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H. Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia. Am J Nephrol 2006;26:276-280
35. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-663
36. Herzog CA, Puumala M, Collins AJ. NHANES III: the distribution of Hb levels related to chronic kidney disease (CKD), diabetes (DM), and congestive heart failure (CHF) (Abstract). J Am Soc Nephrol 2002;13:428A
37. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 2003 (Suppl):S24-S31
38. Burrows L, Muller R. Chronic kidney disease and cardiovascular disease: pathophysiologic links. Nephrol Nurs J 2007;34:55-63
39. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(Suppl.):S16-S23
40. Levin A. Identification of patients and risk factors in chronic kidney disease-evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant 2001;16(Suppl.):57-60
41. McClellan WM, Jurkovitz C, Abramson J. The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease. Eur J Clin Invest 2005;35(Suppl. 3):58-65
42. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006;26:296-306
43. Astor BC, Arnett DK, Brown A, Coresh J. Association of kidney function and Hb with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 2004;43:836-845
44. Joss N, Patel R, Paterson K, Simpson K, Perry C, Stirling C. Anaemia is common and predicts mortality in diabetic nephropathy. Q J Med 2007;100:641-647
45. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997;77:176-185
46. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-760
47. Rossert J, Levin A, Roger SD, Hörl WH, Fouqueray B, Gassmann-Mayer C, Frei D, McClellan WM. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006;47:738-750
48. Ritz E, Laville M, Bilous RW, O'Donoghue D, Scherhag A, Burger U, de Alvaro F; Anemia Correction in Diabetes Study Investigators. Target level for Hb correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007;49:194-207
49. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved Hb outcomes. Kidney Int 2008;74:791-798
50. Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA. Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005;149:408-413
51. KDOQI. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of Hb target. Am J Kidney Dis 2007;50:471-530
52. FDA/Center for Drug Evaluation and Research: Erythropoiesis-stimulating agents (ESAs): epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Aranesp) [article online], 2007. Available from http://www.fda.gov/cder/drug/advisory/RHE200711.htm. Accessed 1 April 2008
53. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher Hb targets. Clin J Am Soc Nephrol 2007;2:1274-1282
54. Dahdah K, Patrie JT, Bolton WK. Intravenous iron dextran treatment in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;36:775-782
55. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with non-dialysis-dependent CKD. Kidney Int 2005;68:2846-2856
56. Fishbane S. Iron management in nondialysis-dependent CKD. Am J Kidney Dis 2007;49:736-743
57. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains Hb concentrations in patients with chronic kidney disease. Clin Nephrol 2005;63:327-334
58. Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005;64:113-123
59. Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Nephrol Dial Transplant 2007;22(Suppl. 4):iv19-iv30
60. Fishbane S. Safety in iron management. Am J Kidney Dis 2003;4(Suppl. 5):18-26
61. Strippoli GF, Craig JC, Manno C, Schena FP. Hb targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004;15:3154-3165
62. Aranesp (darbepoetin alfa) for injection [article online]. Available from http://www.aranesp.com/pdf/aranesp-pi.pdf. Accessed 1 April 2008
63. Procrit (epoitin alfa): for injection [article online]. Available from http://www.procrit.com/procrit/shared/OBI/PI/ProcritBooklet.pdf#page=1. Accessed 1 April 2008
64. Howman R, Kulkarni H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. Nephrol Dial Transplant 2007;22:1462-1464
65. Rossert J, Froissart M, Jacquot C. Anemia management and chronic renal failure progression. Kidney Int 2005;(Suppl):S76-S81
66. Parfrey PS. Target Hb level for EPO therapy in CKD. Am J Kidney Dis 2006;47:171-173